165 related articles for article (PubMed ID: 25153794)
21. Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.
Da Silva Figueiredo Celestino Gomes P; Panel N; Laine E; Pascutti PG; Solary E; Tchertanov L
PLoS One; 2014; 9(5):e97519. PubMed ID: 24828813
[TBL] [Abstract][Full Text] [Related]
22. Analysis of binding energy activity of imatinib and Abl tyrosine kinase domain based on simple consideration for conformational change: An explanation for variation in imatinib effect in mutated type.
Wiwanitkit V
Indian J Cancer; 2009; 46(4):335-6. PubMed ID: 19749465
[TBL] [Abstract][Full Text] [Related]
23. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
24. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Shah NP; Lee FY; Luo R; Jiang Y; Donker M; Akin C
Blood; 2006 Jul; 108(1):286-91. PubMed ID: 16434489
[TBL] [Abstract][Full Text] [Related]
25. Electrochemical evaluation of Abelson tyrosine-protein kinase 1 activity and inhibition by imatinib mesylate and danusertib.
Diculescu VC; Enache TA
Anal Chim Acta; 2014 Oct; 845():23-9. PubMed ID: 25201268
[TBL] [Abstract][Full Text] [Related]
26. In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.
Glekas AP; Pillarsetty NK; Punzalan B; Khan N; Smith-Jones P; Larson SM
J Nucl Med; 2011 Aug; 52(8):1301-7. PubMed ID: 21764785
[TBL] [Abstract][Full Text] [Related]
27. NMR resonance assignment of selectively labeled proteins by the use of paramagnetic ligands.
Cutting B; Strauss A; Fendrich G; Manley PW; Jahnke W
J Biomol NMR; 2004 Oct; 30(2):205-10. PubMed ID: 15702527
[TBL] [Abstract][Full Text] [Related]
28. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.
Aleksandrov A; Simonson T
J Biol Chem; 2010 Apr; 285(18):13807-15. PubMed ID: 20200154
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
Lamontanara AJ; Gencer EB; Kuzyk O; Hantschel O
Biochim Biophys Acta; 2013 Jul; 1834(7):1449-59. PubMed ID: 23277196
[TBL] [Abstract][Full Text] [Related]
30. Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib.
Vajpai N; Strauss A; Fendrich G; Cowan-Jacob SW; Manley PW; Jahnke W; Grzesiek S
Biomol NMR Assign; 2008 Jun; 2(1):41-2. PubMed ID: 19636920
[TBL] [Abstract][Full Text] [Related]
31. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
Lin YL; Meng Y; Jiang W; Roux B
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1664-9. PubMed ID: 23319661
[TBL] [Abstract][Full Text] [Related]
32. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
Frost MJ; Ferrao PT; Hughes TP; Ashman LK
Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
[TBL] [Abstract][Full Text] [Related]
33. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Fernández A; Sanguino A; Peng Z; Ozturk E; Chen J; Crespo A; Wulf S; Shavrin A; Qin C; Ma J; Trent J; Lin Y; Han HD; Mangala LS; Bankson JA; Gelovani J; Samarel A; Bornmann W; Sood AK; Lopez-Berestein G
J Clin Invest; 2007 Dec; 117(12):4044-54. PubMed ID: 18060038
[TBL] [Abstract][Full Text] [Related]
34. Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry.
Zhang HM; Yu X; Greig MJ; Gajiwala KS; Wu JC; Diehl W; Lunney EA; Emmett MR; Marshall AG
Protein Sci; 2010 Apr; 19(4):703-15. PubMed ID: 20095048
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Weisberg E; Choi HG; Ray A; Barrett R; Zhang J; Sim T; Zhou W; Seeliger M; Cameron M; Azam M; Fletcher JA; Debiec-Rychter M; Mayeda M; Moreno D; Kung AL; Janne PA; Khosravi-Far R; Melo JV; Manley PW; Adamia S; Wu C; Gray N; Griffin JD
Blood; 2010 May; 115(21):4206-16. PubMed ID: 20299508
[TBL] [Abstract][Full Text] [Related]
36. Quantification of Single-Molecule Protein Binding Kinetics in Complex Media with Prism-Coupled Plasmonic Scattering Imaging.
Zhang P; Ma G; Wan Z; Wang S
ACS Sens; 2021 Mar; 6(3):1357-1366. PubMed ID: 33720692
[TBL] [Abstract][Full Text] [Related]
37. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
[TBL] [Abstract][Full Text] [Related]
38. A magnetic bead-based protein kinase assay with dual detection techniques.
Zhou G; Sylvester JE; Wu D; Veach DR; Kron SJ
Anal Biochem; 2011 Jan; 408(1):5-11. PubMed ID: 20807497
[TBL] [Abstract][Full Text] [Related]
39. New effective inhibitors of the Abelson kinase.
Kraus GA; Gupta V; Mokhtarian M; Mehanovic S; Nilsen-Hamilton M
Bioorg Med Chem; 2010 Sep; 18(17):6316-21. PubMed ID: 20674368
[TBL] [Abstract][Full Text] [Related]
40. Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
Demetri GD
J Clin Invest; 2007 Dec; 117(12):3650-3. PubMed ID: 18060025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
